Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-24-051658.pdf
0001104659-24-051658.rtf
0001104659-24-051658.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-24-000831.pdf
0000080255-24-000831.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-009536.pdf
0001415889-24-009536.rtf
0001415889-24-009536.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-002762.pdf
0001950047-24-002762.rtf
0001950047-24-002762.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-009169.pdf
0001415889-24-009169.rtf
0001415889-24-009169.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-009009.pdf
0001415889-24-009009.rtf
0001415889-24-009009.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008568.pdf
0001415889-24-008568.rtf
0001415889-24-008568.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008593.pdf
0001415889-24-008593.rtf
0001415889-24-008593.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-002411.pdf
0001950047-24-002411.rtf
0001950047-24-002411.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008124.pdf
0001415889-24-008124.rtf
0001415889-24-008124.xls